6-8% of infants have food hypersensitivity or allergy that often manifest as atopic dermatitis. Formation of intestinal microbiocenosis is occurring during the same age range. There are some research data about the influence of probiotic on clinical course of atopic dermatitis. The aim of this study was to estimate the effect of Bifidobacterium lactis BB-12 (1 х 10(9 0 CFU) and Streptococcus thermophilus TH-4 (1 х 10(8) CFU) administration to infants with atopic dermatitis and cow's milk allergy. We conducted an open randomized prospective clinical study. 60 infants aged of 3-12 months with the diagnosis of atopic dermatitis and allergy to cow's milk protein were enrolled. Children were divided into 2 groups, one of that received probiotic during 4 weeks. Results were estimated with SCORAD scoring after 4 and 8 weeks of treatment. The difference in SCORAD scores between a visit 1 and a visit 3 in infants who in complex treatment received the probiotic strains was 44,05 (3,97) as compared with 38,94 (5,65) in the control group (р<0,05). As a result of our study it is possible to draw a conclusion that administration of probiotics to infants with atopic dermatitis and cow's milk allergy in addition to elimination diet and base treatment improves clinical symptoms of the disease.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Orismilast for moderate-to-severe atopic dermatitis: the potential therapeutic value of a new oral pharmacological alternative.
Br J Dermatol
January 2025
Laboratory of Social Pharmacy and Public Health, Faculty of Pharmacy, University of Coimbra, Portugal, Coimbra, Portugal.
A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: systemic therapy-naive versus -experienced patients.
J Am Acad Dermatol
January 2025
Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
Background: Long-term (2-year) effectiveness of upadacitinib for atopic dermatitis (AD) is unknown in real-world practice.
Objective: To evaluate 96-week real-world effectiveness of upadacitinib in Japanese patients with moderate-to-severe AD, stratified by the presence or absence of prior systemic therapies.
Methods: This prospective study included 327 Japanese patients treated with upadacitinib 15 mg (n = 248) or 30 mg (n = 79).
Sphingolipid metabolism orchestrates establishment of the hair follicle stem cell compartment.
J Cell Biol
April 2025
Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Sphingolipids serve as building blocks of membranes to ensure subcellular compartmentalization and facilitate intercellular communication. How cell type-specific lipid compositions are achieved and what is their functional significance in tissue morphogenesis and maintenance has remained unclear. Here, we identify a stem cell-specific role for ceramide synthase 4 (CerS4) in orchestrating fate decisions in skin epidermis.
View Article and Find Full Text PDFBaricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe Itch.
Dermatol Ther (Heidelb)
January 2025
Department of Dermatology, University of Tsukuba, Tsukuba, Japan.
Introduction: Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score of ≥ 7 ("BARI itch dominant") have been characterized as an important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim to evaluate quality of life (QoL) and functioning outcomes in adult patients with BSA ≤ 40% and itch NRS ≥ 7 at baseline (BL) who received BARI 4 mg in the topical corticosteroid (TCS) combination trial BREEZE-AD7.
Materials: BREEZE-AD7 was a randomized, double-blind, placebo-controlled, parallel-group outpatient study involving adult patients with moderate-to-severe AD who received once-daily placebo or 2-mg or 4-mg BARI in combination with TCS for 16 weeks.
Skin microbiota: pathogenic roles and implications in atopic dermatitis.
Front Cell Infect Microbiol
January 2025
Department of Dermatology, Skin Research Institute of Peking University Shenzhen Hospital, Peking University Shenzhen Hospital, Shenzhen, China.
Atopic dermatitis (AD) is a chronic and inflammatory skin disorder characterized by impaired barrier function and imbalanced immunity. Recent advances have revealed that dysbiosis of skin microbiota plays important roles in the pathogenesis and development of AD. Meanwhile, endogenous and external factors contribute to the dysbiosis of skin microbiota in AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!